SildenafilThird Party Manufacturing in India

Sildenafil is a potent and selective inhibitor of phosphodiesterase-5 (PDE5), the predominant phosphodiesterase isoenzyme responsible for the hydrolytic degradation of cyclic guanosine monophosphate (cGMP) in the corpus cavernosum smooth muscle and pulmonary vascular smooth muscle.

The mechanism is initiated by sexual stimulation or nitric oxide signalling, which triggers the release of nitric oxide from endothelial cells lining the corpus cavernosum and pulmonary vasculature. Nitric oxide diffuses into adjacent smooth muscle cells and activates soluble guanylate cyclase, the enzyme that catalyses the conversion of guanosine triphosphate to cGMP. The accumulating cGMP activates protein kinase G, which phosphorylates multiple downstream targets including calcium-sensitive potassium channels and phospholamban, resulting in reduced intracellular calcium concentration. This calcium depletion causes relaxation of the corpus cavernosum trabecular smooth muscle and dilatation of the helicine arteries, allowing blood to flow into the lacunar spaces and produce penile erection. In the pulmonary circulation, the same pathway reduces pulmonary vascular resistance and right ventricular afterload.

Sildenafil is approximately 4,000-fold more selective for PDE5 than PDE3 and PDE4, but shows only 10-fold selectivity over PDE6 found in retinal photoreceptors, which accounts for the mild and transient visual disturbances reported at higher doses. The therapeutic effect lasts approximately four to six hours, with peak plasma concentration reached 30 to 120 minutes after oral administration.

Therapeutic Uses

Sildenafil is indicated for the treatment of:

• Erectile Dysfunction (ED): The primary indication for sildenafil is the treatment of erectile dysfunction in men, defined as the consistent inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance. Sildenafil is effective across a broad range of aetiologies including psychogenic, organic, and mixed causes. It is also effective in special populations such as men with diabetes, spinal cord injury, radical prostatectomy, hypertension, and depression treated with SSRIs.
• Pulmonary Arterial Hypertension (PAH): Sildenafil is approved for the treatment of pulmonary arterial hypertension (WHO Group I) in adults to improve exercise capacity and delay clinical worsening. It is used as monotherapy or in combination with other PAH therapies such as endothelin receptor antagonists, and has demonstrated significant improvement in six-minute walk distance and haemodynamic parameters.
• Raynaud's Phenomenon: Although not an FDA-approved indication, sildenafil is used off-label to reduce the frequency and severity of Raynaud's attacks, particularly in patients with systemic sclerosis, by improving digital blood flow through pulmonary and peripheral vasodilation.
• High-Altitude Pulmonary Oedema (HAPE): Sildenafil has been used prophylactically and therapeutically to prevent and treat HAPE by reducing pulmonary artery pressure without compromising systemic oxygenation.

Why Manufacturers Choose Sildenafil

Sildenafil is one of the most commercially significant generic molecules in the global pharmaceutical market. India is the largest manufacturer of sildenafil citrate API and finished dosage forms, supplying both domestic and regulated markets including the United States, Europe, and the United Kingdom. The molecule is manufactured in two primary strengths — 50mg and 100mg — which share the same formulation and compression parameters, simplifying production planning. Most manufacturers offer both film-coated and uncoated tablet variants. The market demand is robust year-round with no seasonal fluctuation, and brand loyalty in the PCD franchise segment is exceptionally strong, with patients rarely switching between brands. Export documentation requirements, including CEP, DMF, and COPP filings, are well understood by Indian manufacturers, making sildenafil a staple product in every third-party manufacturing portfolio.

This makes Sildenafil one of the most essential molecules for third party manufacturing in India, with unmatched demand from PCD franchise partners and institutional export buyers across all global regions.